<i>BCR-ABL1</i>-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the <i>JAK2</i>-V617F mutation
-
- AMEMIYA Ayae
- Department of Hematology, Tokyo Medical University
-
- ITO Yoshikazu
- Department of Hematology, Tokyo Medical University
-
- ISHIBASHI Yasunori
- Department of Pathology, Tokyo Medical University Hospital
-
- SAITO Yuu
- Department of Hematology, Tokyo Medical University
-
- KATAGIRI Seiichiro
- Department of Hematology, Tokyo Medical University
-
- SUGURO Tamiko
- Department of Hematology, Tokyo Medical University
-
- ASANO Michiyo
- Department of Hematology, Tokyo Medical University
-
- YOSHIZAWA Seiichiro
- Department of Hematology, Tokyo Medical University
-
- AKAHANE Daigo
- Department of Hematology, Tokyo Medical University
-
- TANAKA Yuko
- Department of Hematology, Tokyo Medical University
-
- FUJIMOTO Hiroaki
- Department of Hematology, Tokyo Medical University
-
- OKABE Seiichi
- Department of Hematology, Tokyo Medical University
-
- GOTOH Moritaka
- Department of Hematology, Tokyo Medical University
-
- TAUCHI Tetsuzo
- Department of Hematology, Tokyo Medical University
-
- OHYASHIKI Kazuma
- Department of Hematology, Tokyo Medical University
Bibliographic Information
- Other Title
-
- <i>JAK2</i>-V617F変異を有する二次性骨髄線維症に発症した<i>BCR-ABL1</i>陽性慢性骨髄性白血病
- 症例報告 第5回日本血液学会関東甲信越地方会 奨励賞 JAK2-V617F変異を有する二次性骨髄線維症に発症したBCR-ABL1陽性慢性骨髄性白血病
- ショウレイ ホウコク ダイ5カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ショウレイショウ JAK2-V617F ヘンイ オ ユウスル ニジセイ コツズイ センイショウ ニ ハッショウ シタ BCR-ABL1 ヨウセイ マンセイ コツズイセイ ハッケツビョウ
Search this article
Abstract
<p>A 53-year-old woman with a 27-year history of myeloproliferative neoplasms came to our hospital because of a marked white blood cell count increase and progressive anemia. Clinical examination demonstrated positivity for BCR-ABL1 and JAK2-V617F mutations. She was given a diagnosis of chronic myeloid leukemia. Using the international scale, a molecular response (MR) 4.5 was achieved after treatment with dasatinib, despite the persistence of marked splenomegaly. The pathological findings of myelofibrosis were demonstrated by bone marrow biopsy. After stopping dasatinib administration for 4 years and 5 months, treatment with ruxolitinib was started. Five months later, the size of her spleen was reduced. We speculated that translocation of BCR-ABL1 might have occurred in a sub-clone of the JAK2-V617F mutated tumor clone.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 58 (4), 298-302, 2017
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390001205035458432
-
- NII Article ID
- 130006882220
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 028193876
-
- PubMed
- 28484156
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed